Stay updated with breaking news from Solid Tumors Version. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KIRKLAND, QC, and MISSISSAUGA, ON, Dec. 21, 2023 /CNW/ - Merck , known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA®, Merck's anti-PD-1 therapy, plus LENVIMA®, an...
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)--Aug 25, 2023--
CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a... | June 5, 2023
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...
Blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel aloneRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe...